Recent Finacing
Recent Raise
Intellia Therapeutics develops CRISPR/Cas9-based ex vivo and in vivo gene‑editing therapeutics, holds a comprehensive IP portfolio, and advances programs for blood disorders, CAR‑T, ophthalmic, CNS, and liver.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Intellia Therapeutics.
